Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jul 21, 2014; 20(27): 9170-9177
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.9170
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.9170
Table 1 Baseline characteristics of the patients enrolled n (%)
Baseline characteristics | Ulcerative colitis | Crohn’s disease | P |
(n = 38) | (n = 59) | ||
Sex | |||
Men | 16 (42.1) | 33 (55.9) | 0.184 |
Women | 22 (57.9) | 26 (44.1) | |
Age (mean ± SD, yr) | 41.9 (14.2) | 38.9 (38.9) | 0.312 |
Duration of disease [median (interquartile range), yr] | 4.5 (2-10.3) | 6 (1-12) | 0.738 |
Smoking status | |||
Non-smoker | 15 (39.5) | 21 (35.6) | 0.003 |
Smoker | 8 (21.1) | 30 (50.8) | |
Ex-smoker | 15 (39.5) | 8 (13.6) | |
Steroid status | |||
Neither steroid dependent nor refractory | 0 | 19 (32.2) | < 0.001 |
Steroid dependent | 21 (55.3) | 33 (55.9) | |
Steroid refractory | 17 (44.7) | 7 (11.9) | |
Steroid use at induction | |||
No | 10 (26.3) | 38 (64.4) | < 0.001 |
Yes | 28 (73.7) | 21 (35.6) | |
Immunomodulator therapy | |||
No | 7 (18.4) | 14 (23.7) | 0.536 |
Yes | 31 (81.6) | 45 (76.3) |
Table 2 Summary of dose intensification
Dose intensification | Ulcerative colitis | Crohn’s disease | P value |
(n = 38) | (n = 59) | ||
Time on infliximab1 [median (interquartile range), mo] | 9 (5.2-12.5) | 13.1 (8.1-23.3) | 0.006 |
Rate of intensification per patient-month | 3.9% | 1.4% | 0.005 |
Time to infliximab intensification [median (interquartile range), mo] | 6.6 (4.2-9.5) | 10.7 (8.9-15.7) | 0.005 |
Table 3 Summary of factors associated with dose intensification in the multivariate analysis
Factor | Adjusted Hazard ratio | 95%CI | P value |
Corticosteroid dependence (yes/no) | 1.359 | 0.425-4.343 | 0.605 |
Age | 1.015 | 0.991-1.040 | 0.216 |
Induction with corticosteroids (yes/no) | 1.258 | 0.521-3.041 | 0.610 |
0Immunomodulator use (yes/no) | 0.510 | 0.242-1.073 | 0.076 |
Disease (ulcerative colitis vs Crohn´s disease) | 2.732 | 1.313-5.686 | 0.007 |
Table 4 Summary of studies of infliximab dose intensification in ulcerative colitis: Proportion of patients who needed infliximab intensification
- Citation: Taxonera C, Olivares D, Mendoza JL, Díaz-Rubio M, Rey E. Need for infliximab dose intensification in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2014; 20(27): 9170-9177
- URL: https://www.wjgnet.com/1007-9327/full/v20/i27/9170.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i27.9170